Hospira DOBUTamine Injection Recall: Discoloration and Particulates Risk
Hospira recalls DOBUTamine Injection vials due to reported discoloration and particulates. Affected units have specific NDC and lot numbers. Consumers should contact Hospira for details.
Lower-risk recall
Discoloration: Firm received complaints of product discoloration and particulates.
Contact the company
What happened, in plain English
Hospira is recalling DOBUTamine Injection vials that may have discoloration or particulates. This could pose a risk to patients receiving IV treatments, so affected users should check their product details and contact Hospira. Read more at govinfonow.com/recall/42486-hospira-dobutamine-injection-recall-discoloration-and-particulates-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/42486-hospira-dobutamine-injection-recall-discoloration-and-particulates-risk · Updated October 9, 2026 · FDA enforcement record: FDA #D-1500-2016
Cite this page
“Hospira DOBUTamine Injection Recall: Discoloration and Particulates Risk.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/42486-hospira-dobutamine-injection-recall-discoloration-and-particulates-risk. Based on FDA recall #D-1500-2016 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1500-2016%22&limit=1).
Why it’s dangerous
Discoloration and particulates in the vial could potentially cause adverse reactions when administered intravenously. The product is intended for IV use only and must be diluted before administration.
Who’s affected
Healthcare professionals using DOBUTamine Injection for IV treatments. Patients receiving this medication are at risk if they use the recalled vials.
How to tell if you have this one
Check for the NDC number 0409-2025-20 and lot number 52175DD on the vial. The product expires October 2016.
- Brand
Hospira- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC number 0409-2025-20 and lot number 52175DD on the vial.
Where it went and when
Where it was distributed
Distributed nationwide, and outside the U.S.
FDA distribution: “Product was distributed nationwide. 23700 units distributed to US and Puerto Rico, and Bahamas was 300 units. 30 units returned by customer and destroyed internally.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide, and outside the U.S.
Recall timeline
FDA terminated this recall 3 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1500-2016 (August 15, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1500-2016 to see it in context.
- Plain-language summary written by qwen3:4b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.